Brief: GRI Bio Says Interim Data From Phase 2a Biomarker Study Is Expected In First Half Of 2024
05/12/2023 16:33
Dec 5 (Reuters) - GRI Bio Inc GRI.O :
* GRI BIO COMMENCES PATIENT ENROLLMENT IN PHASE 2A BIOMARKER
STUDY
EVALUATING LEAD PROGRAM GRI-0621 FOR THE TREATMENT OF IDIOPATHIC
PULMONARY FIBROSIS (“IPF”)
* GRI BIO INC - INTERIM DATA FROM PHASE 2A BIOMARKER STUDY
IS
EXPECTED IN FIRST HALF OF 2024 AND TOPLINE RESULTS ARE EXPECTED
IN SECOND HALF OF 2024
* GRI BIO INC - INTERIM DATA FROM PHASE 2A BIOMARKER STUDY
IS
EXPECTED IN FIRST HALF OF 2024 AND TOPLINE RESULTS ARE EXPECTED
IN SECOND HALF OF 2024
Source text for Eikon: ID:nGNX6gVD22
Further company coverage: GRI.O
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027